A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms
Latest Information Update: 23 Jul 2025
At a glance
- Drugs Fezolinetant (Primary) ; Citalopram; Clonidine; Desvenlafaxine; Escitalopram; Gabapentin; Oxybutynin; Paroxetine; Pregabalin; Serotonin uptake inhibitors; Venlafaxine
- Indications Vasomotor symptoms
- Focus Therapeutic Use
- Acronyms OPTION-VMS
- Sponsors Astellas Pharma Global Development
Most Recent Events
- 11 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2024 Planned End Date changed from 30 Sep 2025 to 30 Nov 2026.
- 18 Jul 2024 Planned primary completion date changed from 30 Sep 2025 to 28 Feb 2026.